SCHEMBL12844319

SCHEMBL12844319

CC(C)(C)OC(=O)Nc1nsc2ccc(N=O)cc12

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PSMB8 P28062 1/20 0.38
▸ STK17B O94768 1/20 0.38
▸ MAP4K4 O95819 1/20 0.35
▸ CYP17A1 P05093 2/20 0.34
▸ ATR Q13535 1/20 0.34
▸ RAB9A P51151 1/20 0.34
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA9 Q16790 1/20 0.33
▸ METAP1 P53582 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ NAMPT P43490 1/20 0.33
▸ SREBF2 Q12772 1/20 0.33
▸ LCK P06239 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8363834 0.82 MAP4K4 (0.41) PSMB8STK17BMAP4K4CYP17A1ATR
SCHEMBL8363843 0.79 MAPT (0.42) PSMB8STK17BRAB9AMEN1MAPT
SCHEMBL15081348 0.78 MAPK1 (0.46) MAP4K4MEN1MAPTMAPK1KMT2A
SCHEMBL25736547 0.70 ALDH1A1 (0.44) CYP17A1CA12CA1CA9MAPK1
SCHEMBL13885934 0.70 CYP17A1 (0.50) PSMB8MAP4K4CYP17A1CA12CA1
SCHEMBL8363848 0.69 PSMB8 (0.34) PSMB8MAP4K4MAPK1
SCHEMBL13633012 0.69 CYP17A1 (0.40) CYP17A1ATRRAB9AMETAP1MEN1
SCHEMBL25736549 0.69 CYP17A1 (0.45) CYP17A1RAB9AMETAP1MEN1MAPT
SCHEMBL24908194 0.68 CYP17A1 (0.50) CYP17A1CA12CA1CA9MEN1
SCHEMBL18966274 0.67 CA12 (0.42) PSMB8MAP4K4CYP17A1RAB9ACA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7902223-B2 For therapy and prophylaxis of thromboses, myocardial infarction, arteriosclerosis, inflammation, apoplexia, angina pectoris, restenosis after angioplasty, claudicatio intermittens, migraine, tumours, tumour diseases and/or tumour metastases MERCK PATENT GMBH (DE) 2011-03-08 — — US disclosed
Send feedback